Eichhorn, F., Klotz, L. V., Bischoff, H., Thomas, M., Lasitschka, F., Winter, H., . . . Eichhorn, M. E. (2019). Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): The NEOMUN trial. BioMed Central.
Chicago-Zitierstil (17. Ausg.)Eichhorn, Florian, Laura Valentina Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann, und Martin E. Eichhorn. Neoadjuvant Anti-programmed Death-1 Immunotherapy by Pembrolizumab in Resectable Nodal Positive Stage II/IIIa Non-small-cell Lung Cancer (NSCLC): The NEOMUN Trial. London: BioMed Central, 2019.
MLA-Zitierstil (9. Ausg.)Eichhorn, Florian, et al. Neoadjuvant Anti-programmed Death-1 Immunotherapy by Pembrolizumab in Resectable Nodal Positive Stage II/IIIa Non-small-cell Lung Cancer (NSCLC): The NEOMUN Trial. BioMed Central, 2019.